Proteasome inhibitors: all 957 studies that test it

Page 1 of 10. Open to participants first (61), then studies with results posted, then the rest; newest registration first within each.

• A Clinical Study of Ixazomib to Reactivate HIV and Reduce HIV Reservoir SizeNot yet recruitingNCT07881809Phase 2
• Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump TherapyNot yet recruitingNCT07715903Phase 1
• A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid TumorsRecruitingNCT07705334Phase 1
• KCD (Carfilzomib/Cyclophosphamide/Dexamethasone) Regimen for the Treatment of Newly Diagnosed POEMS SyndromeRecruitingNCT07652879Phase 2
• Acalabrutinib Maleate and Bortezomib for Patients With HLA AntibodiesNot yet recruitingNCT07635511Phase 3
• Study of Alternative and Approved Dosing Regimens of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT07614360Phase 2
• A Study of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Multiple Myeloma and Moderate Hepatic ImpairmentNot yet recruitingNCT07609706Phase 1
• Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic LymphomaRecruitingNCT07513129Phase 1
• Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple MyelomaRecruitingNCT07479979Phase 1/2
• A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) AmyloidosisRecruitingNCT07224672Phase 2
• A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)RecruitingNCT07222761Phase 3
• Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)Not yet recruitingNCT07072585Phase 2/3
• Fenofibrate Role in the Prophylaxis From Peripheral Neuropathy Induced by Bortezomib, Lenalidomide and Dexamethasone (VRd) Protocol in the Treatment of Patients With Multiple Myeloma (MM)RecruitingNCT07025005Phase 4
• Treatment of Antibody-Mediated Rejection (ABMR) With CarBelRecruitingNCT06918990Phase 1
• Bortezomib Plus Cisplatin in Recurrent or Metastatic Breast CancerRecruitingNCT06900647Phase 1
• Aponermin-Based Bridging Therapy Prior to CAR-T Infusion in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary DiseaseRecruitingNCT06793475Not applicable
• Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary DiseaseRecruitingNCT06627751Phase 2
• Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease DetectionRecruitingNCT06409702Phase 4
• Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)RecruitingNCT06390319Phase 2
• Bortezomib, Pomalidomide, Dexamethasone for Systemic AL AmyloidosisRecruitingNCT06342466Phase 2
• Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Metastatic Non-small Cell Lung CancerRecruitingNCT06249282Phase 1
• A Clinical Study on the Whole-course Management (BCD-KPD-AutoHSCT) Scheme for Patients With RIMMRecruitingNCT06203145Not applicable
• Optimize First-line Treatment for AL Amyloidosis With t (11; 14)RecruitingNCT06192979Not applicable
• Phase 2 Study Applying MRD Techniques for Participants With Previously Untreated Multiple Myeloma Treated With D-VRd Prior To and After High-dose Therapy Followed by ASCT - TAURUSRecruitingNCT06189833Phase 2
• Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple MyelomaRecruitingNCT06140966Phase 2
• A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)RecruitingNCT06083922Phase 2
• Bortezomib-based Regimen for Refractory or Relapsed Acute Lymphoblastic LeukemiaRecruitingNCT06034561Phase 2
• Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL AmyloidosisRecruitingNCT06022939Phase 3
• Carfilzomib, Oral Cyclophosphamide, and Dexamethasone for RRMMNot yet recruitingNCT05909826Phase 2
• Bortezomib for the Treatment of Refractory Rheumatoid ArthritisRecruitingNCT05805891Not applicable
• Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple MyelomaRecruitingNCT05789303Phase 2
• A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)RecruitingNCT05736419Phase 2
• Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple MyelomaRecruitingNCT05722405Phase 4
• GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5RecruitingNCT05695508Phase 2
• Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL)RecruitingNCT05681260Phase 3
• Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma PatientsRecruitingNCT05665140Phase 2/3
• A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple MyelomaRecruitingNCT05651932Phase 1
• The Investigate Efficacy and Safety Evaluation of Bortezomib in Patients With Relapsed/Refractory Immune ThrombocytopeniaRecruitingNCT05599880Phase 2
• Selinexor Plus VRd in High Risk Newly Diagnosed Multiple MyelomaRecruitingNCT05422027Phase 1/2
• Post-Transplant Cyclophosphamide, Bortezomib and Abatacept for the Prevention of Graft-versus-Host-Disease (GvHD)RecruitingNCT05289167Phase 1/2
• Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM PatientsRecruitingNCT05272826Phase 2
• Chemotherapy Combined With Radiotherapy Versus Radiotherapy Alone for Solitary PlasmacytomaRecruitingNCT05248633Phase 2
• Efficacy and Safety of Bortezomib as First-line Treatment of Acquired TTPNot yet recruitingNCT05135442Phase 4
• A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple MyelomaRecruitingNCT04973605Phase 1/2
• Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients.RecruitingNCT04915248Phase 2
• Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple MyelomaRecruitingNCT04822337Phase 1/2
• A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple MyelomaRecruitingNCT04661137Phase 2
• Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE TrialRecruitingNCT04566328Phase 3
• Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients With Renal InsufficiencyRecruitingNCT04240054Phase 2
• Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune EncephalitisRecruitingNCT03993262Phase 2
• Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple MyelomaRecruitingNCT03909412Phase 1
• HLA-Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and BortezomibRecruitingNCT03850366Phase 2
• Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic DiseaseRecruitingNCT03844360Phase 4
• A Nationwide Phase 2 Trial of Patients With Smoldering and Active Multiple Myeloma (MM)Enrolling by invitationNCT03815279Phase 2
• R-VRD Followed by Lenalidomide Maintenance in Patients With Waldenstrom's MacroglobulinemiaRecruitingNCT03697356Phase 2
• Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017RecruitingNCT03643276Phase 3
• VRD as Induction Followed by VR Maintenance in Patients With Newly Diagnosed High Risk Multiple MyelomaRecruitingNCT03641456Phase 2
• Ixazomib Maintenance in Patients With Newly Diagnosed Mantle Cell Lymphoma(MCL)RecruitingNCT03616782Phase 2
• International Study for Treatment of High Risk Childhood Relapsed ALL 2010RecruitingNCT03590171Phase 2
• Childhood Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2015 (ALL-MB 2015)RecruitingNCT03390387Not applicable
• Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/LeukemiaRecruitingNCT03136146Phase 2
• A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis (PALIZADE)TerminatedNCT05781750Phase 2Results posted
• A Study of Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis (PORTOLA)CompletedNCT05569759Phase 2Results posted
• A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell LymphomaCompletedNCT05564052Phase 2Results posted
• Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH TrialActive, not recruitingNCT05497804Phase 2Results posted
• A Study to Evaluate the Safety and Tolerability of Oral Ixazomib in Scleroderma-related Lung Disease PatientsTerminatedNCT04837131Phase 2Results posted
• Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple MyelomaActive, not recruitingNCT04756401Phase 2Results posted
• Open-label Extension to the Phase 2 Crossover Study (PRESIDIO) Evaluating KZR-616 in Patients With PM and DM.CompletedNCT04628936Phase 2Results posted
• A Study of MLN9708 in Japanese Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM)TerminatedNCT04272775Phase 1Results posted
• Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib TripletCompletedNCT04191616Phase 2Results posted
• A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple MyelomaActive, not recruitingNCT04181827Phase 3Results posted
• Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory MyelomaTerminatedNCT04119336Phase 2Results posted
• Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple MyelomaActive, not recruitingNCT04113018Phase 2Results posted
• First in Human Dose Escalation of M3258 as a Single Agent and Expansion Study of M3258 in Combination With DexamethasoneTerminatedNCT04075721Phase 1Results posted
• Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell LymphomaTerminatedNCT04047797Phase 2Results posted
• A Phase 2 Study of KZR-616 to Evaluate Safety and Efficacy in Patients With Active Polymyositis or DermatomyositisCompletedNCT04033926Phase 2Results posted
• High-Dose Post-Transplant Cyclophosphamide and Bortezomib (CyBor) for the Prevention of Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)CompletedNCT03945591Phase 2Results posted
• Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM TrialCompletedNCT03941860Phase 3Results posted
• Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple MyelomaCompletedNCT03934684Phase 4Results posted
• A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaCompletedNCT03859427Phase 3Results posted
• PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic LymphomaActive, not recruitingNCT03817320Phase 1/2Results posted
• LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple MyelomaCompletedNCT03773107Phase 1/2Results posted
• Ixazomib and Pevonedistat in Treating Patients With Multiple Myeloma That Has Come Back or Does Not Respond to TreatmentCompletedNCT03770260Phase 1Results posted
• Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT)CompletedNCT03748953Phase 3Results posted
• Marizomib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial, and Spinal Cord EpendymomaTerminatedNCT03727841Phase 2Results posted
• Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL)TerminatedNCT03547700Phase 1/2Results posted
• A Study of Carfilzomib Plus Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma at US Community Oncology CentersTerminatedNCT03512353Phase 2Results posted
• Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom MacroglobulinemiaTerminatedNCT03506373Phase 2Results posted
• Nab-sirolimus in Recurrent High Grade Glioma and Newly Diagnosed GlioblastomaCompletedNCT03463265Phase 2Results posted
• Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma Resistant to ChemotherapyTerminatedNCT03457142Phase 2Results posted
• A Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM)CompletedNCT03439293Phase 2Results posted
• A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based TherapyCompletedNCT03416374Phase 4Results posted
• A Study of KZR-616 in Patients With SLE With and Without Lupus NephritisCompletedNCT03393013Phase 1/2Results posted
• A Phase III Trial of With Marizomib in Patients With Newly Diagnosed GlioblastomaCompletedNCT03345095Phase 3Results posted
• A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell LymphomaCompletedNCT03323151Phase 1/2Results posted
• A Study of Daratumumab in Patients With Newly Diagnosed Multiple MyelomaActive, not recruitingNCT03290950Phase 2Results posted
• Carfilzomib With or Without Rituximab in the Treatment of Waldenstrom Macroglobulinemia or Marginal Zone LymphomaTerminatedNCT03269552Phase 2Results posted
• Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple MyelomaTerminatedNCT03256045Phase 2Results posted
• Ixazomib for DesensitizationCompletedNCT03213158Phase 2Results posted
• Ixazomib Citrate, Pomalidomide, Dexamethasone, Stem Cell Transplant in Treating Relapsed or Refractory Multiple MyelomaCompletedNCT03202628Phase 2Results posted

← Proteasome inhibitors overview